Combination of Stereotactic Radiosurgery with Immunotherapy: Is It a New Treatment Option for Brain Metastases?

Brain metastases (BMs) represent the commonest intracranial tumours which occur approximately 30% of all adult patients presenting with solid cancers. The BMs do not only reduce the survival expectations but negatively alter the quality of life measures as well. For decades, surgery and whole-brain radiotherapy (WBRT) constituted the traditional treatment options with limited efficacy for the BMs. However, the unsatisfactory local control and ultimate survival outcomes led to a paradigm change, and stereotactic radiosurgery (SRS) has been executed as an alternative to surgery and WBRT or to augment the outcomes of each treatment when used in conjunction with them. In spite of the impressive improvements in the local control rates, yet the desired survival Review Article Kucuk et al.; IRJO, 3(1): 9-19, 2020; Article no.IRJO.55909 10 results were not achieved with SRS mainly due to the deaths ascribed to the extracranial systemic disease progression or unavoidably fatal distant brain recurrences. In this regard, as of late, numerous immunotherapeutics have been shown to improve the outcomes of various cancers, such as the locally advanced non-small-cell lung cancers. Recognizing the fact that the immunotherapy is becoming one of the indispensable components of standard treatment protocols for many tumour primaries, this review aimed to evaluate the efficacy and safety of the use of novel immunotherapeutics with standard SRS for BMs.

[1]  S. Buti,et al.  Effectiveness and safety of "real" concurrent stereotactic radiotherapy and immunotherapy in metastatic solid tumors: a systematic review. , 2019, Critical reviews in oncology/hematology.

[2]  V. Esposito,et al.  Stereotactic radiosurgery combined with nivolumab or Ipilimumab for patients with melanoma brain metastases: evaluation of brain control and toxicity , 2019, Journal of Immunotherapy for Cancer.

[3]  M. Del Vecchio,et al.  Combination of Immunotherapy and Brain Radiotherapy in Metastatic Melanoma: A Retrospective Analysis , 2019, Oncology Research and Treatment.

[4]  J. Jaboin,et al.  Concurrent Radiosurgery and Immune Checkpoint Inhibition: Improving Regional Intracranial Control for Patients With Metastatic Melanoma , 2019, American journal of clinical oncology.

[5]  K. McDonald,et al.  Concurrent versus non-concurrent immune checkpoint inhibition with stereotactic radiosurgery for metastatic brain disease: a systematic review and meta-analysis , 2018, Journal of Neuro-Oncology.

[6]  A. Redig,et al.  Immunotherapy and Symptomatic Radiation Necrosis in Patients With Brain Metastases Treated With Stereotactic Radiation , 2018, JAMA oncology.

[7]  H. Shih,et al.  Improved Overall Survival and Locoregional Disease Control With Concurrent PD-1 Pathway Inhibitors and Stereotactic Radiosurgery for Lung Cancer Patients With Brain Metastases. , 2018, International journal of radiation oncology, biology, physics.

[8]  Derek E. Smith,et al.  Immune checkpoint inhibitors and radiosurgery for newly diagnosed melanoma brain metastases , 2018, Journal of Neuro-Oncology.

[9]  Cheng Yu,et al.  Stereotactic radiosurgery and ipilimumab for patients with melanoma brain metastases: clinical outcomes and toxicity , 2018, Journal of Neuro-Oncology.

[10]  E. Lanoy,et al.  Tolerance and outcomes of stereotactic radiosurgery combined with anti-programmed cell death-1 (pembrolizumab) for melanoma brain metastases , 2018, Melanoma research.

[11]  A. Niemierko,et al.  The impact of timing of immunotherapy with cranial irradiation in melanoma patients with brain metastases: intracranial progression, survival and toxicity , 2018, Journal of Neuro-Oncology.

[12]  J. Knisely,et al.  Immunotherapy Plus Stereotactic Radiosurgery: Building on the Promise of Precision Medicine for CNS Malignancies-PART 1: Principles of Combined Treatment. , 2018, Oncology.

[13]  C. Bettegowda,et al.  Concurrent Immune Checkpoint Inhibitors and Stereotactic Radiosurgery for Brain Metastases in Non-Small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma. , 2017, International journal of radiation oncology, biology, physics.

[14]  Y. Yamada,et al.  Melanoma brain metastases treated with stereotactic radiosurgery and concurrent pembrolizumab display marked regression; efficacy and safety of combined treatment , 2017, Journal of Immunotherapy for Cancer.

[15]  K. Patel,et al.  Ipilimumab and Stereotactic Radiosurgery Versus Stereotactic Radiosurgery Alone for Newly Diagnosed Melanoma Brain Metastases , 2017, American journal of clinical oncology.

[16]  S. Woo,et al.  Peri-SRS Administration of Immune Checkpoint Therapy for Melanoma Metastatic to the Brain: Investigating Efficacy and the Effects of Relative Treatment Timing on Lesion Response. , 2017, World neurosurgery.

[17]  B. Stea,et al.  Improved time to disease progression in the brain in patients with melanoma brain metastases treated with concurrent delivery of radiosurgery and ipilimumab , 2017, Oncoimmunology.

[18]  J. Sheehan,et al.  The effect of timing of stereotactic radiosurgery treatment of melanoma brain metastases treated with ipilimumab. , 2017, Journal of neurosurgery.

[19]  James J. Evans,et al.  Phase 1 Study of Ipilimumab Combined With Whole Brain Radiation Therapy or Radiosurgery for Melanoma Patients With Brain Metastases. , 2016, International journal of radiation oncology, biology, physics.

[20]  H. Kluger,et al.  Timing and type of immune checkpoint therapy affect the early radiographic response of melanoma brain metastases to stereotactic radiosurgery , 2016, Cancer.

[21]  B. Fox,et al.  Optimizing Timing of Immunotherapy Improves Control of Tumors by Hypofractionated Radiation Therapy , 2016, PloS one.

[22]  M. Postow,et al.  Irradiation and immunotherapy: From concept to the clinic , 2016, Cancer.

[23]  G. Gibney,et al.  Clinical outcomes of melanoma brain metastases treated with stereotactic radiation and anti-PD-1 therapy. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[24]  Y. Yamada,et al.  Stereotactic radiosurgery for melanoma brain metastases in patients receiving ipilimumab: safety profile and efficacy of combined treatment. , 2015, International journal of radiation oncology, biology, physics.

[25]  J. Wolchok,et al.  Immune-priming of the Tumor Microenvironment by Radiotherapy: Rationale for Combination With Immunotherapy to Improve Anticancer Efficacy , 2015, American journal of clinical oncology.

[26]  I. Stratford,et al.  Acquired resistance to fractionated radiotherapy can be overcome by concurrent PD-L1 blockade. , 2014, Cancer research.

[27]  D. Gomez,et al.  Combining Radiation and Immunotherapy: A New Systemic Therapy for Solid Tumors? , 2014, Cancer Immunology Research.

[28]  K. Shirai,et al.  Survival of melanoma patients with brain metastases treated with ipilimumab and stereotactic radiosurgery , 2014, Cancer medicine.

[29]  C. Drake,et al.  Immune Modulation and Stereotactic Radiation: Improving Local and Abscopal Responses , 2013, BioMed research international.

[30]  Brady T. West,et al.  Ipilimumab and radiation therapy for melanoma brain metastases , 2013, Cancer medicine.

[31]  C. June,et al.  Radiation and immunotherapy: a synergistic combination. , 2013, The Journal of clinical investigation.

[32]  J. Golfinos,et al.  Ipilimumab in melanoma with limited brain metastases treated with stereotactic radiosurgery , 2013, Melanoma research.

[33]  J. Knisely,et al.  Radiosurgery for melanoma brain metastases in the ipilimumab era and the possibility of longer survival. , 2012, Journal of neurosurgery.

[34]  K. Iwamoto,et al.  Maximizing tumor immunity with fractionated radiation. , 2012, International journal of radiation oncology, biology, physics.

[35]  Drew M. Pardoll,et al.  The blockade of immune checkpoints in cancer immunotherapy , 2012, Nature Reviews Cancer.

[36]  A. Möller,et al.  Inflammation and immune surveillance in cancer. , 2012, Seminars in cancer biology.

[37]  N. Kawashima,et al.  Fractionated but Not Single-Dose Radiotherapy Induces an Immune-Mediated Abscopal Effect when Combined with Anti–CTLA-4 Antibody , 2009, Clinical Cancer Research.

[38]  Lieping Chen,et al.  Inhibitory B7-family molecules in the tumour microenvironment , 2008, Nature Reviews Immunology.

[39]  T. Okazaki,et al.  PD-1 and PD-1 ligands: from discovery to clinical application. , 2007, International immunology.

[40]  A. Lanfranco,et al.  CTLA-4 and PD-1 Receptors Inhibit T-Cell Activation by Distinct Mechanisms , 2004, Molecular and Cellular Biology.

[41]  W. Schuette.  Treatment of brain metastases from lung cancer: chemotherapy. , 2004, Lung cancer.

[42]  P. Wen,et al.  Management of brain metastases. , 1999, Oncology.

[43]  J. Bluestone,et al.  CD28/B7 system of T cell costimulation. , 1996, Annual review of immunology.

[44]  P. Linsley,et al.  Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors. , 1994, Immunity.

[45]  J. Gribben,et al.  Cloning of B7-2: a CTLA-4 counter-receptor that costimulates human T cell proliferation. , 1993, Science.

[46]  P. Brown,et al.  Treatment of brain metastases with stereotactic radiosurgery and immune checkpoint inhibitors: An international meta-analysis of individual patient data. , 2018, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[47]  P. Marchetti,et al.  Brain Metastases: Surgical Treatment and Overall Survival. , 2017, World neurosurgery.

[48]  G. Freeman,et al.  The B7 family revisited. , 2005, Annual review of immunology.